To include your compound in the COVID-19 Resource Center, submit it here.

FDA panel concludes Translarna data inconclusive in DMD

FDA's Peripheral and Central Nervous System Drugs Advisory Committee voted overwhelmingly that efficacy data for Translarna ataluren to treat nonsense mutations in Duchenne muscular dystrophy (DMD) were inconclusive.

Ten of 11 panel members voted that although it is possible Translarna from PTC Therapeutics Inc. (NASDAQ:PTCT)

Read the full 447 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE